Buy me a coffee
Home › FDA recalls › Cisatracurium Besylate Injection USP
CLASS III · LowFDA

SOMERSET THERAPEUTICS LLC recalls Cisatracurium Besylate Injection USP

📅 Nov 26, 2025 · 📍 Nationwide
Recalling company
SOMERSET THERAPEUTICS LLC
Product
Cisatracurium Besylate Injection USP, 10 mg/5 mL* (2mg/mL), 10 x 5 mL Single-dose Vials per Carton, Rx Only, Manufactured for: Somerset Therapeutics, LLC, Hollywood, FL 33024, Made in India, Single-dose 5 mL vial NDC 70069-141-01; 10x5 mL single dose vial per Carton NDC 70069-141-10.
Reason
Subpotent product:out of specification assay results observed during long term stability testing.
Classification
Class III – not likely to cause adverse health consequences
Recall date
Nov 26, 2025
Reported
Dec 24, 2025
Distribution
Nationwide in the USA
Status
Ongoing
Quantity
52,340 5mL vials
Lot / codes
Lot#: A240438, Exp Date 1/31/26, A250125, Exp Date 8/31/26
Company location
Somerset, NJ
Recall type
Voluntary: Firm initiated
Recall number
D-0236-2026
Agency
U.S. Food and Drug Administration (FDA)

View official FDA notice ↗ Search recall number D-0236-2026 in the FDA Enforcement Report. Also see FDA recall press releases.

If you use this product, check the lot, NDC or model number against the official notice and follow its instructions. Do not stop a prescribed medicine or remove a medical device without talking to your doctor or pharmacist. Report problems to FDA MedWatch. FoodRecallNow summarizes public FDA data and is not medical advice.